FDA Approval Recommendation for CAR T-Cell Therapy
FDA advisory committee unanimously approves first personalized cellular therapy developed at Penn for pediatric and young adult leukemia.
Read moreFollowing A Patient Story From Transfusion Medicine to Hemepath Rotations
When I started my pathology residency, I never expected to have such a moving patient experience.
read moreClinical Trial for Personalized Immunotherapy in Glioblastoma
Results from nine patients with brain tumor reported at AACR.
Read morePartnership to Produce Gene Therapies
Plans to open a 145,000-square-foot cell and gene therapy manufacturing plant at the Philadelphia Navy Yard.
Read moreNew Patents for Pathology Research Team
Issued for technologies in pioneering personalized cellular therapy CTL019 for patients with leukemia and lymphoma.
Read moreLatest Results of Investigational Cellular Therapy CTL019 at ASH
Highlights of the new trial results include a response rate of more than 90 percent among pediatric ALL patients, and results from the first lymphoma trials testing the approach, including a 100 percent response rate among follicular lymphoma patients and 45 percent response rate among those with diffuse large B cell lymphoma.
Read more
